XmAb662

· Xencor, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for XmAb662, covering 2024-08-23 to 2024-08-23. Get the full timeline:

Most recent: Clinical Trial Update: A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors [Phase 1]